Presentation is loading. Please wait.

Presentation is loading. Please wait.

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,

Published by禧 仇 Modified over 5 years ago

Similar presentations

Presentation on theme: "A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,"— Presentation transcript:

1 A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek, PhD, Tingting Ge, PhD, Pina D'Angelo, MSc, Xuejun Liu, PhD  Journal of Allergy and Clinical Immunology  Volume 132, Issue 4, Pages e6 (October 2013) DOI: /j.jaci Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Participant accounting. Treatment A, 1 mL × 10 mg/mL JNJ oral solution plus 1× placebo tablet; treatment B, 1 mL of placebo oral solution plus 1× 60-mg pseudoephedrine tablet; and treatment C, 1 mL of placebo oral solution plus 1× placebo tablet. aOther screen failures include patients who were withdrawn in error (n = 2), withdrawn from the study (n = 2), prohibited medication use (n = 1), lost to follow-up (n = 1), and unable to have blood drawn for assessments (n = 1). Participants randomized into the study should pass the EEC screening and must have had a decrease of 10% or greater in the MCA in either nostril, as assessed by using AcR before exposure (before entering the EEC) and after exposure (measured in the chamber) and must have a minimum TNSS of 6 of 12, including a score of at least 2 for congestion, on at least 1 diary card before dosing. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 The mean changes from baseline in TNSSs and individual nasal symptom scores (intent-to-treat population) in the JNJ , pseudoephedrine, and placebo groups. Note: The severity of nasal symptoms (runny nose, itchy nose, nasal congestion, and sneezing) were recorded every 30 minutes while in the EEC on a 4-point scale (0, absent; 1, mild; 2, moderate; and 3, severe). A, TNSSs. B, Runny nose scores. C, Itchy nose scores. D, Nasal congestion scores. E, Sneezing scores. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 2 The mean changes from baseline in TNSSs and individual nasal symptom scores (intent-to-treat population) in the JNJ , pseudoephedrine, and placebo groups. Note: The severity of nasal symptoms (runny nose, itchy nose, nasal congestion, and sneezing) were recorded every 30 minutes while in the EEC on a 4-point scale (0, absent; 1, mild; 2, moderate; and 3, severe). A, TNSSs. B, Runny nose scores. C, Itchy nose scores. D, Nasal congestion scores. E, Sneezing scores. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 3 Effect of EEC ragweed exposure on protein concentrations obtained from nasal lavage specimens of participants in the placebo group in period 1. Heat map of the log2 ratios of 13 proteins tested between post-EEC samples in period 1 and corresponding samples of prescreening EEC (baseline) from 12 patients of the placebo group. Each row represents 1 tested protein, and each column represents 1 patient. Red and blue indicate increases and decreases from baseline values, respectively. Hierarchic clustering on the proteins illustrates 2 major groups of proteins that exhibit distinctive expression patterns across patients. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig E1 Study design. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig E2 Cytokine and ECP levels in response to EEC ragweed exposure in the placebo group for each treatment period. A, IL-4. B, IL-5. C, IL-13. D, Human ECP. E, Albumin. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8 Fig E3 Effect of JNJ and pseudoephedrine on cytokine and ECP levels in response to EEC ragweed exposure during period 1. A, Treatment effect on IL-4. B, Treatment effect on IL-5. C, Treatment effect on IL-13. D, Treatment effect on human ECP. E, Treatment effect on albumin. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,"

Similar presentations

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,
Nasal challenge with allergen leads to maxillary sinus inflammation

Nasal challenge with allergen leads to maxillary sinus inflammation
Nasal filters for the treatment of allergic rhinitis: A randomized, double-blind, placebo- controlled crossover clinical trial  Peter Kenney, BA, BSc,

Nasal filters for the treatment of allergic rhinitis: A randomized, double-blind, placebo- controlled crossover clinical trial  Peter Kenney, BA, BSc,
The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam,

The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam,
Information technology–based approaches to reducing repeat drug exposure in patients with known drug allergies  Kathrin M. Cresswell, MSc, Aziz Sheikh,

Information technology–based approaches to reducing repeat drug exposure in patients with known drug allergies  Kathrin M. Cresswell, MSc, Aziz Sheikh,
A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,
Joseph A. Odhiambo, MMed, Hywel C. Williams, PhD, Tadd O

Joseph A. Odhiambo, MMed, Hywel C. Williams, PhD, Tadd O
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.

Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.
Information technology–based approaches to reducing repeat drug exposure in patients with known drug allergies  Kathrin M. Cresswell, MSc, Aziz Sheikh,

Information technology–based approaches to reducing repeat drug exposure in patients with known drug allergies  Kathrin M. Cresswell, MSc, Aziz Sheikh,
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil.

Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil.
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,

Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.
Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Similar presentations

Ads by Google